Methods for treating drug resistant cancers
AssigneeThe Regents of the University of California
InventorsDavid CHERESH, Sara Weis, Erika COSSET
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorsDavid CHERESH, Sara Weis, Erika COSSET
Estimating the term…
Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (αvβ3) pathway, wherein the sensitivity is determined by methods as provided herein.
A method for determining whether a tumor or a cancer cell will be sensitive to (or can be killed or induced to senescence by) a treatment targeting the integrin avb3 (αvβ3) pathway, comprising:
The method of any of the preceding claims, wherein the determining or having determined if the tumor or the cancer cell expresses both avb3+ and Glut3+ comprises determining if the tumor or the cancer cell expresses both an avb3+ and a Glut3+ protein, or both an avb3+ and a Glut3+ message (mRNA, transcript), or both an avb3+ and a Glut3+ protein and message,
The method of any of the preceding claims, wherein the determining or having determined if the tumor or the cancer cell expresses a marker consistent with a Classical or Proneural subtype or has a Glut3 addicted gene/molecular signature, optionally expressing at least one of the genes at levels as listed in FIG. 11 or FIG. 23, comprises determining or having determined if the tumor or the cancer cell expresses an mRNA and/or a protein consistent with a Classical or a Proneural subtype, or has a Glut3 addicted gene/molecular signature, optionally expressing an mRNA or protein from a gene as listed in FIG. 11 or FIG. 23,
The method of any of the preceding claims, wherein the determining or having determined if the tumor or the cancer cell expresses both avb3+ and Glut3+ comprises taking or isolating a cell or a sample of cells, optionally cancer cells or tumors cells, from a patient, optionally a patient tentatively diagnosed or definitely diagnosed with the tumor or cancer, optionally GBM, and determining if the cell or sample of cells expresses both avb3+ and Glut3+ and is Glut-3 addicted.
Dependencies are inferred from the claim text.